Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

Johnson & Johnson (JNJ) reported a strong Q2 2025, surpassing top and bottom-line estimates and raising full-year guidance, with sales now projected at $93.2B-$93.4B and EPS at $10.80-$10.90. This performance was largely driven by robust growth in the Innovative Medicines unit, which successfully offset a 42.7% sales decline from Stelara's loss of exclusivity, alongside improved results in the MedTech segment. Despite ongoing challenges including talc lawsuits and potential pharma tariffs, J&J's diversified business model, active pipeline, and strategic acquisitions are anticipated to accelerate growth from 2026, contributing to a 6% stock price increase post-announcement.

Analysis

Johnson & Johnson demonstrated robust operational strength in its Q2 2025 results, beating expectations and raising full-year guidance. The company increased its sales forecast to a range of $93.2 billion to $93.4 billion and its adjusted EPS guidance to $10.80-$10.90, reflecting confidence in its core business and favorable currency tailwinds. This performance is particularly noteworthy as the Innovative Medicines unit grew 2.4% organically, successfully absorbing the impact of a 42.7% sales decline in its blockbuster drug Stelara following its loss of exclusivity. Growth was propelled by strong performance from key drugs like Darzalex and Erleada, alongside significant contributions from new launches such as Carvykti and Tecvayli. The MedTech segment also showed improvement, with sales rising 6.1% operationally, driven by recent acquisitions and organic growth, though it continues to face headwinds from China's volume-based procurement program. Despite the positive results, which sent the stock up over 6%, significant overhangs remain. The company faces more than 62,000 talc-related lawsuits, with its third bankruptcy settlement attempt recently rejected, and potential political risk from proposed pharmaceutical tariffs. While J&J's valuation, at a 14.74 forward P/E, is slightly above its industry, it remains below its five-year average, suggesting the market is balancing strong execution against these lingering uncertainties.

Key Decisions for Investors

• Investors should recognize that the Q2 earnings beat and guidance raise validate J&J's strategy of offsetting the Stelara patent cliff with a strong pipeline and diversified business model, reinforcing the bull case for the company's operational execution.
• It is crucial to monitor developments in the talc litigation, as the failure of the bankruptcy settlement strategy reintroduces significant legal and financial uncertainty that is not fully priced into the stock.
• While the company's performance is strong, investors should remain aware of external risks, including persistent pricing pressure in China's MedTech market and the potential for future U.S. pharmaceutical tariffs, which could impact long-term profitability.
• Given the stock's 15.1% year-to-date outperformance, consider the current valuation relative to its peers and historical levels, while acknowledging the stability offered by its 63rd consecutive annual dividend increase as a component of total return.